Analysts expect Express Scripts (NASDAQ:ESRX) to announce earnings of $2.23 per share for the current quarter, Zacks reports. Twelve analysts have issued estimates for Express Scripts’ earnings, with the highest EPS estimate coming in at $2.34 and the lowest estimate coming in at $2.18. Express Scripts reported earnings per share of $1.73 in the same quarter last year, which suggests a positive year over year growth rate of 28.9%. The company is expected to report its next earnings results on Tuesday, July 24th.
On average, analysts expect that Express Scripts will report full-year earnings of $9.14 per share for the current year, with EPS estimates ranging from $9.00 to $9.35. For the next year, analysts forecast that the firm will post earnings of $9.54 per share, with EPS estimates ranging from $8.84 to $10.45. Zacks’ EPS averages are a mean average based on a survey of analysts that follow Express Scripts.
Express Scripts (NASDAQ:ESRX) last posted its quarterly earnings data on Wednesday, May 2nd. The company reported $1.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.76 by $0.01. The business had revenue of $24.77 billion during the quarter, compared to the consensus estimate of $24.80 billion. Express Scripts had a return on equity of 25.41% and a net margin of 4.59%. Express Scripts’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $1.33 earnings per share.
A number of analysts have weighed in on ESRX shares. Zacks Investment Research downgraded Express Scripts from a “buy” rating to a “hold” rating in a report on Friday, March 2nd. Jefferies Group set a $91.00 price target on Express Scripts and gave the stock a “buy” rating in a report on Wednesday, February 28th. BidaskClub upgraded Express Scripts from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Sanford C. Bernstein downgraded Express Scripts from a “market perform” rating to an “underperform” rating and increased their price target for the stock from $55.80 to $77.50 in a report on Tuesday, January 30th. Finally, Bank of America started coverage on Express Scripts in a report on Tuesday, February 27th. They set an “underperform” rating and a $77.00 price target for the company. Four analysts have rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $82.50.
In other news, VP Everett Neville sold 4,895 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $75.26, for a total value of $368,397.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christine Houston sold 19,889 shares of the firm’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $76.69, for a total value of $1,525,287.41. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of ESRX. Swedbank bought a new position in Express Scripts in the 4th quarter valued at about $111,016,000. Leucadia National Corp bought a new position in shares of Express Scripts during the 4th quarter worth approximately $567,000. Xact Kapitalforvaltning AB lifted its position in shares of Express Scripts by 5.2% during the 4th quarter. Xact Kapitalforvaltning AB now owns 102,730 shares of the company’s stock worth $7,668,000 after buying an additional 5,123 shares in the last quarter. Glenmede Trust Co. NA lifted its position in shares of Express Scripts by 1.6% during the 4th quarter. Glenmede Trust Co. NA now owns 422,156 shares of the company’s stock worth $31,508,000 after buying an additional 6,448 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new position in shares of Express Scripts during the 4th quarter worth approximately $406,000. Institutional investors own 85.82% of the company’s stock.
Express Scripts traded down $1.10, reaching $76.65, during trading hours on Friday, MarketBeat Ratings reports. 85,768 shares of the company’s stock were exchanged, compared to its average volume of 3,876,875. The company has a current ratio of 0.69, a quick ratio of 0.56 and a debt-to-equity ratio of 0.81. Express Scripts has a twelve month low of $55.80 and a twelve month high of $85.07. The company has a market cap of $42.98 billion, a P/E ratio of 10.80, a PEG ratio of 0.97 and a beta of 0.98.
Express Scripts Company Profile
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.